Ocular Therapeutix, Inc. Sustainability Profile
Ocular Therapeutix, Inc., commonly referred to as Ocular Therapeutix, is a pioneering biopharmaceutical company headquartered in the United States. Founded in 2014, the company focuses on the development and commercialisation of innovative therapies for ocular diseases and conditions. With a strong presence in the ophthalmic industry, Ocular Therapeutix has made significant strides in creating unique drug delivery systems that enhance patient outcomes. The company’s flagship products include Dextenza, a sustained-release dexamethasone insert for post-surgical inflammation, and OTX-TP, a novel treatment for glaucoma. These offerings distinguish Ocular Therapeutix in the market, showcasing its commitment to advancing ocular health. Recognised for its innovative approach, Ocular Therapeutix continues to solidify its position as a leader in the ophthalmic therapeutics sector, driving forward with a robust pipeline of products aimed at addressing unmet medical needs.
DitchCarbon Score
How does Ocular Therapeutix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ocular Therapeutix, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ocular Therapeutix, Inc.'s reported carbon emissions
Ocular Therapeutix, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). As a result, Ocular Therapeutix, Inc. does not have publicly available information regarding its carbon footprint or climate commitments. This lack of data may reflect a broader trend within the industry, where many companies are still in the early stages of developing comprehensive sustainability strategies. In summary, without specific emissions data or reduction initiatives, Ocular Therapeutix, Inc. has yet to demonstrate a commitment to addressing carbon emissions or climate change within its operational framework.
How Carbon Intensive is Ocular Therapeutix, Inc.'s Industry?
How Carbon Intensive is Ocular Therapeutix, Inc.'s Location?
Ocular Therapeutix, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ocular Therapeutix, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
